In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug ...

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...

The Inflation Reduction Act includes an exemption for orphan drugs for a single indication, but experts say this is far from ...

In advance of this week's CDC vaccine advisory meeting, HHS Secretary Robert F. Kennedy Jr. restacked the committee, claiming ...